Journal article
Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses
Nicola L Bird, Matthew R Olson, Aeron C Hurt, Christine M Oshansky, Ding Yuan Oh, Patrick C Reading, Brendon Y Chua, Yilun Sun, Li Tang, Andreas Handel, David C Jackson, Stephen J Turner, Paul G Thomas, Katherine Kedzierska
PLOS ONE | PUBLIC LIBRARY SCIENCE | Published : 2015
Abstract
CD8(+) T cells directed against conserved viral regions elicit broad immunity against distinct influenza viruses, promote rapid virus elimination and enhanced host recovery. The influenza neuraminidase inhibitor, oseltamivir, is prescribed for therapy and prophylaxis, although it remains unclear how the drug impacts disease severity and establishment of effector and memory CD8(+) T cell immunity. We dissected the effects of oseltamivir on viral replication, inflammation, acute CD8(+) T cell responses and the establishment of immunological CD8(+) T cell memory. In mice, ferrets and humans, the effect of osteltamivir on viral titre was relatively modest. However, prophylactic oseltamivir treat..
View full abstractRelated Projects (2)
Grants
Awarded by Australian National Health and Medical Research Council (NHMRC) Project Grant
Awarded by NHMRC Program Grant
Awarded by US government funds through the National Institute of Allergy and Infectious Diseases, the National Institutes of Health
Funding Acknowledgements
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The work was supported by Australian National Health and Medical Research Council (NHMRC) Project Grant to KK (GNT1008854), NHMRC Program Grant to SJT (GNT567122), a CASS Foundation Project Grant (to KK), and US government funds through the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, under contract numbers HHSN266200700005C and HHSN272201400006C (Centers of Excellence for Influenza Research and Surveillance) to PT and ALSAC to PT. KK is a NHMRC Career Development Fellow Level 2 and SJT is an ARC Future Fellow Level 3. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.